Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
Key Highlights
- ➤USPTO published U.S. patent application for ZUNVEYL’s proprietary benzgalantamine manufacturing process
- ➤Application covers manufacturing efficiency, product quality, impurity control and commercial-scale production
- ➤Technology includes benzgalantamine salts, pharmaceutical compositions and critical product-characteristic controls
- ➤Publication strengthens Alpha Cognition’s planned intellectual property protection around benzgalantamine and ZUNVEYL
Expert Statements
Michael McFadden, Chief Executive Officer of Alpha Cognition
“The publication of this U.S. patent application represents another step in our strategy to build broad intellectual property protection around benzgalantamine and ZUNVEYL®”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“The application is focused on manufacturing innovations designed to support consistent product quality, impurity control and scalable production.”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“We believe these capabilities are important to the long-term commercial potential of ZUNVEYL® and our broader benzgalantamine development programs.”
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent Application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026, as U.S. Patent Application Publication No. US 2026/0297103 A1.
Get started
Create a free account to read the full story.